We are live on ! Find out more
QNRX

Quoin Pharmaceuticals
QNRX

8 hedge funds and large institutions have $321K invested in Quoin Pharmaceuticals in 2022 Q2 according to their latest regulatory filings, with 4 funds opening new positions, 1 increasing their positions, 1 reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

300% more first-time investments, than exits

New positions opened: 4 | Existing positions closed: 1

60% more funds holding

Funds holding: 5 → 8 (+3)

0% more ownership

Funds ownership: 0% → 0% (+0%)

0% more repeat investments, than reductions

Existing positions increased: 1 | Existing positions reduced: 1

23% less capital invested

Capital invested by funds: $419K → $321K (-$98K)

Holders
8
Holders Change
+3
Holders Change %
+60%
% of All Funds
0.13%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
4
Increased
1
Reduced
1
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Citadel Advisors
Citadel Advisors
Florida
+$15.9K
2
TSS
Two Sigma Securities
New York
+$11.9K
3
Citigroup
Citigroup
New York
+$7.96K
4
Renaissance Technologies
Renaissance Technologies
New York
+$7.96K
5
UBS Group
UBS Group
Switzerland
+$7.96K

Top Sellers

Rank Fund Capital Flow
1
VF
Virtu Financial
New York
-$57K
2
HF
HRT Financial
New York
-$3.98K
Name Holding Trade Value Shares
Change 		Change in
Stake
Ameriprise
1
Ameriprise
Minnesota
$256K – – –
Renaissance Technologies
2
Renaissance Technologies
New York
$29K +$7.96K +2 +20%
Citadel Advisors
3
Citadel Advisors
Florida
$9K +$15.9K +4 New
TSS
4
Two Sigma Securities
New York
$7K +$11.9K +3 New
Geode Capital Management
5
Geode Capital Management
Massachusetts
$6K – – –
Citigroup
6
Citigroup
New York
$6K +$7.96K +2 New
HF
7
HRT Financial
New York
$4K -$3.98K -1 -33%
UBS Group
8
UBS Group
Switzerland
$4K +$7.96K +2 New
VF
9
Virtu Financial
New York
– -$57K -8 Closed

QNRX Hedge Fund Activity: Q2 2022 in Review

8 of the 5,937 institutional investors tracked by Wall St. Rank reported a position in Quoin Pharmaceuticals (QNRX) for Q2 2022, worth a combined $321K — down 23% from $419K a quarter earlier.

Buyers outnumbered sellers: 4 funds opened new QNRX positions and 1 closed out — a net gain of 3 holders — while 1 added to existing stakes and 1 trimmed.

The largest buyer was Citadel Advisors, opening a new position worth an estimated $15.9K. The largest seller was Virtu Financial, exiting entirely with an estimated $57K sold.

  • 8 institutional investors held Quoin Pharmaceuticals (QNRX) as of Q2 2022, up from 5 in Q1 2022.
  • Funds reported $321K of Quoin Pharmaceuticals stock for Q2 2022, down 23% quarter-over-quarter.
  • 4 funds opened new Quoin Pharmaceuticals positions in Q2 2022 and 1 closed out, a net change of +3 holders.
  • The largest Quoin Pharmaceuticals buyer in Q2 2022 was Citadel Advisors, an estimated $15.9K added.
  • The largest Quoin Pharmaceuticals seller in Q2 2022 was Virtu Financial, an estimated $57K sold.

Based on aggregated 13F filings for Q2 2022.